Reliable T Cell Expansion with CellGenix^®️ Recombinant Human Interleukin-2 (IL-2)

Cell and gene therapies have seen rapid approvals over the past decade and the pipeline of new candidates continues to grow. The ability to quickly develop robust protocols and consistently manufacture these therapies depends on the reliability of raw and ancillary materials. For example, Interleukin-2 (IL-2) is a cytokine commonly used as a raw material in cell-based therapies such as CAR-T to promote T cell expansion. This application note compares two grades of IL-2 (CellGenix^®️ Preclinical rh IL-2 and a FDA-approved IL-2) in the growth, viability, and subpopulation distribution of Peripheral Blood Mononuclear Cells (PBMCs).
 
Read to learn how:

• T cell expansion with IL-2 works across multiple donors and media
• CellGenix^®️ Preclinical rh IL-2 promotes desired T cell phenotypes for CAR-T therapy
• CellGenix^®️ Preclinical cytokines can smooth the transition from development into clinical production